(Q40707780)

22 September 2017

Chemotherapy for germ cell tumours: prophylactic ciprofloxacin reduces the incidence of neutropenic fever (English)

1 reference

22 September 2017

Counsell R

1

1 reference

PubMed ID

7986759

22 September 2017

Pratt J

series ordinal

2

1 reference

PubMed ID

7986759

22 September 2017

Williams MV

series ordinal

3

1 reference

22 September 2017

1 January 1994

1 reference

22 September 2017

1 reference

22 September 2017

6

1 reference

22 September 2017

4

1 reference

22 September 2017

232-236

1 reference

Antimicrobial prophylaxis against infection in neutropenic patients

22 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980292-4

7 January 2021

The new fluorinated quinolones for antimicrobial prophylaxis in neutropenic cancer patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980292-4

7 January 2021

Antimicrobial prophylaxis in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980292-4

7 January 2021

Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980292-4

7 January 2021

Comparison of norfloxacin with cotrimoxazole for infection prophylaxis in acute leukemia. The trade-off for reduced gram-negative sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980292-4

7 January 2021

Prophylactic co-trimoxazole versus norfloxacin in neutropenic children--perspective randomized study.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980292-4

7 January 2021

Ofloxacin versus co-trimoxazole for prevention of infection in neutropenic patients following cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980292-4

7 January 2021

Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980292-4

7 January 2021

Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980292-4

7 January 2021

Emergence of ciprofloxacin-resistant coagulase-negative staphylococcal skin flora in immunocompromised patients receiving ciprofloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980292-4

7 January 2021

Quinolone antimicrobial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980292-4

7 January 2021

Plasmid-mediated 4-quinolone resistance: a real or apparent absence?

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980292-4

7 January 2021

Quinolone resistance. Susceptibility data from a 300-bed community hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980292-4

7 January 2021

Mortality in patients with testicular cancer: report of the Anglia and Trent testicular tumour groups

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2980292-4

7 January 2021

10.1016/S0936-6555(05)80292-4

Identifiers

DOI

1 reference

22 September 2017

1 reference

PubMed ID

7986759